Tatcı Ebru, Uslu Biner İnci, Emir Suna, Tanyıldız Hikmet Gülşah, Özmen Özlem, Alagöz Engin, Gökçek Atila, Şahin Gürses
Atatürk Chest Diseases and Thoracic Surgery Training and Research Hospital, Department of Nuclear Medicine, Ankara, Turkey Phone: +90 505 914 53 61 E-mail:
Mol Imaging Radionucl Ther. 2017 Feb 5;26(1):9-16. doi: 10.4274/mirt.94914.
To compare standardized uptake values (SUV) derived from pre-treatment F-fluorodeoxyglucose (FDG) positron emission tomography/computed tomography (PET/CT) imaging and clinical prognostic factors in pediatric patients with Hodgkin lymphoma (HL).
Pre-treatment FDG PET/CT findings of 28 children with HL were evaluated in this retrospective study. Metabolic tumor volume (MTV), SUV normalized by weight (SUV), lean body mass (SUV), body surface area (SUV) and plasma glucose levels of tumors (SUV) were calculated using pre-treatment FDG PET/CT scan images. These metabolic parameters were correlated with clinical factors [age, sex, number of lymph node groups, presence of splenic involvement, bulky mediastinal disease, Ann Arbor stage, serum white blood cell (WBC) count, erythrocyte sedimentation rate (ESR), serum albumin and hemoglobin levels].
SUV, SUV, SUV, SUV and MTV were higher in patients with stage III-IV disease, bulky tumor and ≥3 lymph node groups (p<0.05). SUV and SUV were higher in patients with splenic involvement (p<0.05). There was no significant correlation between these metabolic parameters and sex, ESR, levels of albumin and WBC (p>0.05). SUV and SUV were higher in patients with anemia (p<0.05). Additionally, significant increases were detected in SUV, MTV, and SUV with increasing age (p=0.005, p=0.027, and p=0.009, respectively). SUV and SUV had no significant correlation with age (p>0.05).
Metabolic parameters derived from pre-treatment FDG PET/CT may have an important role in predicting high-risk disease in patients with HL. Also, SUV and SUV may be better markers than SUV in the quantitative evaluation of FDG PET/CT scans in pediatric patients.
比较霍奇金淋巴瘤（HL）患儿治疗前氟脱氧葡萄糖（FDG）正电子发射断层扫描/计算机断层扫描（PET/CT）成像得出的标准化摄取值（SUV）与临床预后因素。
本回顾性研究评估了28例HL患儿的治疗前FDG PET/CT检查结果。使用治疗前FDG PET/CT扫描图像计算代谢肿瘤体积（MTV）、体重标准化SUV（SUV）、去脂体重标准化SUV（SUV）、体表面积标准化SUV（SUV）以及肿瘤的血浆葡萄糖水平标准化SUV（SUV）。将这些代谢参数与临床因素[年龄、性别、淋巴结组数量、脾受累情况、巨大纵隔疾病、Ann Arbor分期、血清白细胞（WBC）计数、红细胞沉降率（ESR）、血清白蛋白和血红蛋白水平]进行关联分析。
III-IV期疾病、巨大肿瘤和≥3个淋巴结组的患者中，SUV、SUV、SUV、SUV和MTV更高（p<0.05）。脾受累患者的SUV和SUV更高（p<0.05）。这些代谢参数与性别、ESR、白蛋白水平和WBC之间无显著相关性（p>0.05）。贫血患者的SUV和SUV更高（p<0.05）。此外，随着年龄增长，SUV、MTV和SUV显著升高（分别为p=0.005、p=0.027和p=0.009）。SUV和SUV与年龄无显著相关性（p>0.05）。
治疗前FDG PET/CT得出的代谢参数可能在预测HL患者的高危疾病方面具有重要作用。此外，在儿童患者的FDG PET/CT扫描定量评估中，SUV和SUV可能比SUV是更好的标志物。
